Supravenous Hyperpigmentation Induced by Vinorelbine

Cecchi, R; Tuci, F.; Giomi, Andrea; Innocenti, F.

doi:10.1159/000247152

Cited by 19 publications

(19 citation statements)

References 3 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Single instances have been reported of supravenous hyperpigmentation at the infusion site [149] and a localised necrolysing epidermal reaction. Such reactions can be attenuated by administering the drug over 6 to 10 minutes according to recommended guidelines (section 5).…”

Section: Other Eventsmentioning

confidence: 99%

Vinorelbine

Goa¹,

Faulds²

1994

Drugs & Aging

View full text Add to dashboard Cite

Vinorelbine is a semisynthetic vinca alkaloid with a broad spectrum of antitumour activity. The drug is effective as a single agent in inoperable/advanced non-small cell lung cancer (NSCLC), producing objective response rates of about 15 to 30%, and as first-line or later chemotherapy for metastatic spread in advanced breast cancer. Combining vinorelbine with standard chemotherapeutic regimens improves response rates in these indications compared with vinorelbine monotherapy: in NSCLC response rates increase to 30 to 50% when vinorelbine is administered with cisplatin. Importantly, survival was prolonged by a further 9 weeks with this combination in a trial in > 600 patients with NSCLC. Comparative trials evaluating vinorelbine in women with advanced breast cancer are few at present. However, results suggest greater efficacy for vinorelbine than for melphalan as second-line chemotherapy, and similar efficacy for vinorelbine plus doxorubicin compared with doxorubicin plus 2 other drugs as first-line chemotherapy. Vinorelbine has tended to yield superior response rates when compared with vindesine, and appears to have greater haematological toxicity (i.e. granulocytopenia) but less neurological toxicity (peripheral neuropathy, constipation, loss of deep tendon reflexes) than this agent. Myelosuppression is the most frequent cause of vinorelbine treatment delay or dose reduction. Other consequences of vinorelbine therapy are those typically seen with antineoplastic agents, such as diarrhoea, nausea and vomiting, and alopecia. However, these are rarely severe. Early clinical investigations indicate that the antitumour effects of vinorelbine in other malignancies including ovarian carcinoma, lymphoma and head and neck cancer warrant further exploration, as does the efficacy of the drug relative to standard approaches and its possible beneficial effects on quality of life of cancer patients. Clarification is also required of the feasibility of an oral dosage form, which in preliminary investigations has shown some efficacy in NSCLC, but a variable response rate and high incidence of gastrointestinal disturbances in women with breast cancer. Thus, vinorelbine as a single agent or combined palliative therapy is effective against advanced NSCLC, and as first- or second-line chemotherapy in advanced breast cancer. This semisynthetic vinca alkaloid has a manageable tolerability profile and potential for use in other malignancies and as an oral formulation. With these attributes, vinorelbine is a valuable option which extends the range of treatments available for these difficult-to-treat malignancies.

show abstract

Section: Other Eventsmentioning

confidence: 99%

Vinorelbine

Goa¹,

Faulds²

1994

Drugs & Aging

View full text Add to dashboard Cite

show abstract

“…The lesions develop between 24 h and 15 days after intravenous cytotoxic drug infusion and subside spontaneously after 1–3 weeks often leaving residual hyperpigmentation 2 . PSSHE is characterized by hyperpigmented streaks that follow the superficial venous network in a linear or serpentine pattern 3–6 . It may be preceded by erythema or appear as a hyperpigmented macule without erythema 3,4,6 .…”

Section: Discussionmentioning

confidence: 99%

“…PSSHE is characterized by hyperpigmented streaks that follow the superficial venous network in a linear or serpentine pattern 3–6 . It may be preceded by erythema or appear as a hyperpigmented macule without erythema 3,4,6 . Although these eruptions usually occur at the injection site, serpentine hyperpigmented streaks occurring in areas other than the infusion site have also been reported 4,5 .…”

Section: Discussionmentioning

confidence: 99%

“…Systemic and cutaneous side‐effects of these agents are seen frequently because of this wide usage. Erythematous or hyperpigmented linear streaks following the superficial venous network at the injection site have been reported after administration of several chemotherapeutics 1–6 . We recently diagnosed a patient who had hyperpigmented linear streaks at the site of docetaxel injection, following the route of the superficial venous network of the anterior aspect of the right forearm and distal arm.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Persistent serpentine supravenous hyperpigmented eruption associated with docetaxel

Aydoğan¹,

Kavak²,

Parlak³

et al. 2005

Acad Dermatol Venereol

View full text Add to dashboard Cite

Various mucocutaneous reactions have been reported with the use of systemic docetaxel. We describe a 47-year-old man who developed a persistent serpentine supravenous hyperpigmented eruption (PSSHE), beginning at the site of docetaxel injection and spreading along the superficial venous network in the anterior aspect of the right forearm and distal arm. The eruption occurred after the first infusion of docetaxel following insufficient venous washing. A second infusion was administered through a vein in the other forearm, but this time, abundant venous washing was performed and a similar eruption did not occur. To our knowledge, this is the second report of docetaxel-induced supravenous discoloration and we discussed the terminology and mechanism of this unique reaction.

show abstract

“…As the local reactions including phlebitis are usually mild and of limited duration, they are often not reported spontaneously by the patients. In rare cases, however, persistent hyperpigmentation [4], local epidermal necrolysis [5], and ulceration requiring surgical treatment [6,7] have been reported. The purpose of this study was to examine the usefulness of adding human albumin to the vinorelbine solution in preventing venous irritation.…”

Section: The Addition Of Human Albumin To Vinorelbine Solution Prevenmentioning

confidence: 99%

The Addition of Human Albumin to Vinorelbine Solution Prevents Venous Irritation

Weiss¹,

Wellens²

1999

Oncol Res Treat

View full text Add to dashboard Cite

Background: Vinorelbine (Navelbine^® ) is a promising and well-tolerated new vinca alkaloid with significant clinical activity in breast cancer and non-small-cell lung cancer. Although rarely severe, local reactions including phlebitis are relatively common after infusions of vinorelbine into peripheral veins. Patients and Methods: We examined if the addition of human albumin to the infusion solution of vinorelbine could prevent the development of local irritation. 34 patients with breast cancer were prospectively enrolled in the study. Human albumin (25 ml of a 20% solution) was added to 100 ml of the infusion solution immediately prior to administration. Results: No local toxicity occurred after 81 infusions in 18 patients who had human albumin added to their vinorelbine infusion from the beginning. In contrast, local inflammation developed in 11 of 16 patients who initially did not receive albumin. When human albumin was introduced in these patients, local toxicity did not reappear after a total of 34 subsequent infusions of vinorelbine. Conclusion:The addition of human albumin to the infusion solution of vinorelbine effectively prevents local irritation including phlebitis.

show abstract

Supravenous Hyperpigmentation Induced by Vinorelbine

Cited by 19 publications

References 3 publications

Vinorelbine

Vinorelbine

Persistent serpentine supravenous hyperpigmented eruption associated with docetaxel

The Addition of Human Albumin to Vinorelbine Solution Prevents Venous Irritation

Contact Info

Product

Resources

About